Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Splenic volume may be a useful indicator of the protective effect of bevacizumab against the hepatic sinusoidal obstruction syndrome induced by oxaliplatin.